Dr. Logan McDaneld
Claim this profileSt. Mary's Medical Center
Studies Stroke
Studies Ischemic Injury
5 reported clinical trials
11 drugs studied
Affiliated Hospitals
Clinical Trials Logan McDaneld is currently running
Apixaban vs Aspirin
for Stroke Prevention in Atrial Fibrillation After Brain Bleed
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Recruiting1 award Phase 36 criteria
Tissue Kallikrein
for Ischemic Stroke
This is a Phase 2/3 study evaluating the safety and efficacy of DM199 (rinvecalinase alfa) in treating participants with moderate stroke severity, who present within 24 hours of Acute Ischemic Stroke (AIS) onset due to small and medium vessel occlusions. This study focuses on participants with limited treatment options. Participants who have or will receive mechanical thrombectomy (MT) are not eligible for participation. Additionally, participants who have received fibrinolytics are excluded unless they experience a persistent neurological deficit of moderate severity six or more hours after fibrinolytic treatment. Participants considered for this trial should not be denied the use of standard of care (SoC) AIS therapies, such as fibrinolytics or MT, when appropriate. The double-blinded study will be randomized and placebo-controlled at up to approximately 100 sites.
Recruiting0 awards Phase 2 & 37 criteria
More about Logan McDaneld
Clinical Trial Related5 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Logan McDaneld has experience with
- Apixaban
- Aspirin
- Recombinant Human Tissue Kallikrein
- Crizanlizumab Injection
- P2Y12
- Prophylactic Heparin
Breakdown of trials Logan McDaneld has run
Stroke
Ischemic Injury
Coronavirus
Atrial Fibrillation
Intracranial Arteriosclerosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Logan McDaneld specialize in?
Logan McDaneld focuses on Stroke and Ischemic Injury. In particular, much of their work with Stroke has involved treating patients, or patients who are undergoing treatment.
Is Logan McDaneld currently recruiting for clinical trials?
Yes, Logan McDaneld is currently recruiting for 3 clinical trials in Grand Junction Colorado. If you're interested in participating, you should apply.
Are there any treatments that Logan McDaneld has studied deeply?
Yes, Logan McDaneld has studied treatments such as Apixaban, Aspirin, Recombinant human tissue kallikrein.
What is the best way to schedule an appointment with Logan McDaneld?
Apply for one of the trials that Logan McDaneld is conducting.
What is the office address of Logan McDaneld?
The office of Logan McDaneld is located at: St. Mary's Medical Center, Grand Junction, Colorado 81501 United States. This is the address for their practice at the St. Mary's Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.